Novavax Revenue 2006-2021 | NVAX

Novavax annual/quarterly revenue history and growth rate from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Novavax revenue for the quarter ending September 30, 2021 was $0.179B, a 13.9% increase year-over-year.
  • Novavax revenue for the twelve months ending September 30, 2021 was $1.204B, a 487.9% increase year-over-year.
  • Novavax annual revenue for 2020 was $0.476B, a 2448.48% increase from 2019.
  • Novavax annual revenue for 2019 was $0.019B, a 45.57% decline from 2018.
  • Novavax annual revenue for 2018 was $0.034B, a 9.98% increase from 2017.
Novavax Annual Revenue
(Millions of US $)
2020 $476
2019 $19
2018 $34
2017 $31
2016 $15
2015 $36
2014 $31
2013 $21
2012 $22
2011 $15
2010 $0
2009 $0
2008 $1
2007 $2
2006 $2
2005 $5
Novavax Quarterly Revenue
(Millions of US $)
2021-09-30 $179
2021-06-30 $298
2021-03-31 $447
2020-12-31 $280
2020-09-30 $157
2020-06-30 $36
2020-03-31 $3
2019-12-31 $9
2019-09-30 $3
2019-06-30 $3
2019-03-31 $4
2018-12-31 $6
2018-09-30 $8
2018-06-30 $11
2018-03-31 $10
2017-12-31 $10
2017-09-30 $8
2017-06-30 $7
2017-03-31 $6
2016-12-31 $5
2016-09-30 $3
2016-06-30 $3
2016-03-31 $4
2015-12-31 $6
2015-09-30 $7
2015-06-30 $14
2015-03-31 $10
2014-12-31 $7
2014-09-30 $8
2014-06-30 $8
2014-03-31 $7
2013-12-31 $9
2013-09-30 $5
2013-06-30 $4
2013-03-31 $4
2012-12-31 $5
2012-09-30 $6
2012-06-30 $7
2012-03-31 $5
2011-12-31 $6
2011-09-30 $5
2011-06-30 $3
2011-03-31 $1
2010-12-31 $0
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31 $0
2009-09-30 $0
2009-06-30 $0
2009-03-31 $0
2008-12-31 $0
2008-09-30 $0
2008-06-30 $0
2008-03-31 $0
2007-12-31 $0
2007-09-30 $1
2007-06-30 $-0
2007-03-31 $0
2006-12-31 $0
2006-09-30 $1
2006-06-30 $1
2006-03-31 $1
2005-12-31 $2
2005-09-30 $2
2005-06-30 $2
2005-03-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.009B $0.476B
NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $138.972B 8.78
Bio-Rad Laboratories (BIO.B) United States $16.992B 34.48
QIAGEN (QGEN) Netherlands $11.128B 18.85
Biohaven Pharmaceutical Holding (BHVN) United States $7.780B 0.00
Emergent Biosolutions (EBS) United States $2.486B 8.94
Arcus Biosciences (RCUS) United States $2.230B 0.00
Myovant Sciences (MYOV) United Kingdom $1.231B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.064B 0.00
Zymeworks (ZYME) Canada $0.466B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Ambrx Biopharma (AMAM) United States $0.193B 0.00
Enzo Biochem (ENZ) United States $0.153B 19.75